INDOCO vs WOCKPHARMA: Stock Comparison

INDOCO REMEDIES vs WOCKHARDTUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. WOCKHARDT shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INDOCO leads 3; WOCKPHARMA leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INDOCOWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹2,421 Cr
₹33,908 Cr
P/E RatioWOCKPHARMA has the lower reading
445.9x
75.68x
P/B RatioINDOCO has the lower reading
2.67x
6.27x
EPSINDOCO has the higher reading
₹7.04
₹6.58
Book ValueContext only
₹100.98
₹325
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹33,908 Cr vs ₹2,421 Cr
P/E Ratio
WOCKPHARMA has a lower P/E
75.68x vs 445.9x
P/B Ratio
INDOCO has a lower P/B
2.67x vs 6.27x
EPS
INDOCO has higher earnings per share
₹7.04 vs ₹6.58
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 21.9%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
14.31% vs -39.61%
Qtr Profit Growth
WOCKPHARMA has stronger quarterly profit growth
0% vs -20.51%
ROE
WOCKPHARMA has a higher ROE
10.28% vs -0.51%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOWOCKPHARMA
Live Price₹262.51₹2,088.7
Day Change-3.69%7.08%
Volume3.69 L35.58 L
52-Week High₹332.2₹2,422.3
52-Week Low₹162.19₹1,086.7
Distance from 52W High-20.98%-13.77%

Valuation

MetricINDOCOWOCKPHARMA
Market Cap₹2,421 Cr₹33,908 Cr
P/E Ratio445.9x75.68x
P/B Ratio2.67x6.27x
EPS₹7.04₹6.58
Book Value₹100.98₹325
Dividend Yield0%0%

Growth

MetricINDOCOWOCKPHARMA
Revenue Growth (TTM YoY)21.9%26%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth14.31%-39.61%
Qtr Profit Growth-20.51%0%

Profitability & Leverage

MetricINDOCOWOCKPHARMA
ROE-0.51%10.28%
ROCE4.26%10.37%
Net Margin-5.31%3.3%
Operating Margin4.57%28.35%
Debt to Equity0.64x0.57x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOWOCKPHARMA
Promoter Holding58.86%49.08%
FII Holding1.27% 0.33 pp7.22% 0.13 pp
DII Holding17.68% 0.47 pp9.24% 1.72 pp
Public Holding22.04% 0.14 pp34.44% 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOCO REMEDIES and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.